GlassScriptPhysician profile
Varshasb Broumand
NPI 1154329720
$117,819.41
in general payments reported to CMS, 2019-2025
49 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $2,889 · 2021: $3,575 · 2022: $19K · 2023: $34K · 2024: $31K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Consulting Fee: $22K · Honoraria: $13K · Food and Beverage: $9,994 · Travel and Lodging: $3,550 · Entertainment: $69.06 · Education: $25.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,447.76 |
| Consulting Fee | $22,102.75 |
| Honoraria | $12,930.00 |
| Food and Beverage | $9,994.23 |
| Travel and Lodging | $3,550.30 |
| Entertainment | $69.06 |
| Education | $25.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $42,900.36 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $33,630.72 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $9,419.96 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $9,090.42 | 2021-2025 | |
| Akebia Therapeutics INC | $7,158.38 | 2019-2025 | Vafseo, Auryxia |
| Amgen INC. | $5,426.64 | 2019-2025 | Krystexxa, Tavneos, Repatha |
| Fresenius USA Marketing, INC. | $943.78 | 2019-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $888.12 | 2019-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $844.88 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $838.97 | 2020-2025 | Acthar |
| Allergan, INC. | $576.54 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $550.66 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $469.06 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $435.86 | 2019-2025 | Jynarque |
| Mallinckrodt Enterprises LLC | $401.92 | 2019 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $365.92 | 2019-2022 | |
| Novo Nordisk INC | $361.19 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Aurinia Pharma U.S., INC. | $343.92 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $320.96 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $306.96 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $293.21 | 2020-2024 | Benlysta, Jesduvroq |
| Alexion Pharmaceuticals, INC. | $280.87 | 2019-2024 | Soliris, Ultomiris |
| W. L. Gore & Associates, INC. | $232.61 | 2019 | |
| Lilly USA, LLC | $203.76 | 2020-2024 | Mounjaro |
| Ardelyx, INC. | $200.84 | 2024-2025 | Ibsrela |
| Shield Therapeutics INC | $148.04 | 2024-2025 | |
| Abbvie INC. | $143.17 | 2021-2022 | |
| Cormedix INC. | $143.11 | 2024-2025 | Defencath, Defencath |
| Corcept Therapeutics | $124.98 | 2025 | Korlym |
| Angiodynamics, INC. | $115.66 | 2023-2024 | Auryon Laser System 100-120 Vac |
| Sonavex, INC. | $86.81 | 2024 | Echosure, Echomark |
| Nxstage Medical, INC. | $69.45 | 2019 | |
| Keystone Dental INC. | $69.06 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.85 | 2024-2025 | Jardiance |
| Omeros Corporation | $52.00 | 2019 | |
| Amarin Pharma, INC. | $42.72 | 2019-2020 | |
| Genzyme Corporation | $36.54 | 2023-2024 | |
| Amicus Therapeutics, INC. | $35.20 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $29.44 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.04 | 2022 | |
| Organogenesis INC. | $25.00 | 2023 | Puraply |
| Argon Medical Devices, INC. | $24.04 | 2021 | |
| Daiichi Sankyo INC. | $22.33 | 2021 | |
| Arbor Pharmaceuticals, INC. | $22.33 | 2020 | |
| Cook Medical LLC | $20.57 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.32 | 2023 | Xifaxan |
| Strongbridge US INC. | $11.65 | 2020 | |
| Cardiovascular Systems INC. | $8.59 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varshasb Broumand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.